Welcome to our dedicated page for Solventum Corporation SEC filings (Ticker: SOLV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Solventum Corporation (NYSE: SOLV) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures filed with the U.S. Securities and Exchange Commission. These documents help investors, analysts and other stakeholders understand Solventum’s financial performance, portfolio actions, capital structure and governance as it operates in the medical instruments and supplies sector.
Solventum uses current reports on Form 8-K to disclose a variety of material events. Examples include 8-K filings reporting quarterly financial results, such as third-quarter 2025 earnings, which incorporate press releases detailing segment performance, non-GAAP measures and updated guidance. Other 8-K filings describe material definitive agreements and their completion, such as the transaction agreement and subsequent closing of the sale of certain assets and liabilities related to Solventum’s purification and filtration business to Thermo Fisher Scientific Inc.
Additional 8-K filings cover capital markets and balance sheet activities, including the commencement, upsizing and pricing of cash tender offers for specified series of senior notes, and an underwriting agreement relating to the sale of shares by a selling shareholder. Governance and leadership changes, such as the appointment of a Chief Commercial Officer and the departure of a segment leader, are also reported on Form 8-K, along with information about related compensation and severance arrangements.
On Stock Titan, users can review these filings alongside AI-powered summaries that explain key points in clear language. This includes highlighting where Solventum discusses its “Transform for the Future” initiative, outlines risk factors, or provides pro forma financial information related to divestitures. The filings page is also a resource for tracking Solventum’s capital allocation strategy, including debt reduction, note tender offers and the authorization of a share repurchase program, as disclosed in its official documents.
Solventum Corp’s Chief Accounting Officer, Mary T. Wilcox, exercised previously granted restricted stock units into common shares. On March 27, 2026, she converted 5,199 RSUs, receiving an equal number of common shares. A portion of these shares was then withheld to cover tax obligations.
Of the acquired shares, 1,591 common shares were disposed of through tax withholding at a price of $62.76 per share, leaving Wilcox with 5,256 common shares held directly after the transactions. The RSUs were fully vested at the time of exercise, indicating this was a routine compensation-related event rather than an open-market trade.
Solventum Corp director Carrie Smith Cox exercised restricted stock units into common shares. On March 27, 2026, she exercised 6,336 Restricted Stock Units, each representing one share of common stock upon settlement. Following the exercise, she directly holds 11,484 shares of Solventum common stock. The filing states the RSUs were fully vested at the time of exercise.
Solventum Corp director Susan D. DeVore exercised fully vested Restricted Stock Units to receive Common Stock as equity compensation. She converted 1,980 RSUs, each representing a contingent right to one share of Common Stock, into 1,980 shares at an exercise price of $0.00 per share.
After the transaction, she directly holds 5,544 shares of Solventum Common Stock. The filing shows a routine derivative exercise/conversion with no open‑market buying or selling activity.
Solventum Corp director Shirley Ann Edwards exercised restricted stock units into common shares. On March 27, 2026, she converted 1,980 Restricted Stock Units, each representing a right to receive one share of common stock when settled. This derivative exercise resulted in 1,980 shares of Solventum common stock credited to her direct holdings.
Following the transaction, Edwards directly holds 5,544 shares of Solventum common stock. The filing describes this as an exercise or conversion of a derivative security, not an open-market purchase or sale, and the RSUs involved were reported as fully vested.
Solventum Corp director Glenn A. Eisenberg exercised equity awards to increase his direct share ownership. He converted 1,980 fully vested Restricted Stock Units into 1,980 shares of Common Stock at no exercise price. Following the transaction, he directly holds 5,544 Solventum common shares. This was an option/RSU exercise, not an open-market purchase or sale.
Solventum Corp director Harris Bernard A Jr exercised previously granted Restricted Stock Units, converting 1,980 RSUs into 1,980 shares of Common Stock at a stated price of $0.00 per share. Following this vesting and settlement event, he now directly holds 5,544 shares of Solventum Common Stock. The RSUs were fully vested before settlement, meaning the shares were delivered as part of his existing equity compensation rather than through an open-market purchase or sale.
Solventum Corp director Wilson Darryl L. exercised restricted stock units into common shares. He converted 1,980 Restricted Stock Units into 1,980 shares of Common Stock at a stated price of $0.00 per share, reflecting settlement of fully vested RSUs. Following the transaction, he directly holds 5,544 shares of Solventum common stock.
Solventum Corp director Wendell Amy McBride exercised fully vested Restricted Stock Units into common stock. McBride converted 1,980 RSUs, each representing one share of common stock, at an exercise price of $0.00 per unit. Following the transaction, McBride directly holds 7,019 shares of Solventum common stock. This filing reflects a compensation-related derivative exercise rather than an open-market purchase or sale.
Solventum Corp director John H. Weiland exercised equity awards rather than trading in the open market. On March 27, 2026, he exercised 1,980 Restricted Stock Units, each converting into one share of Solventum common stock at a stated price of $0.00 per share.
Following this RSU settlement, Weiland now directly holds 5,544 shares of Solventum common stock. The filing shows no open-market purchases or sales, only the conversion of fully vested RSUs into common shares as part of his equity compensation.
Solventum Corp director Mily Elizabeth exercised fully vested restricted stock units to receive common shares. On March 27, 2026, she exercised 1,980 RSUs, each representing one share of common stock, at an exercise price of $0.00 per unit.
Following the conversion, she directly holds 5,606 shares of Solventum common stock. The RSU award is now fully settled with no RSUs remaining outstanding from this grant, and there were no open-market purchases or sales reported in this filing.